CoChat

Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance

Open access
Kumashiro, Naoki, Beddow, Sara A., Vatner, Daniel F., Majumdar, Sachin K., Cantley, Jennifer L., Guebre-Egziabher, Fitsum, Fat, Ioana, Guigni, Blas, Jurczak, Michael J., Birkenfeld, Andreas L., Kahn, Mario, Perler, Bryce K., Puchowicz, Michelle A., Manchem, Vara Prasad, Bhanot, Sanjay, Still, Christopher D., Gerhard, Glenn S., Petersen, Kitt Falk, Cline, Gary W., Shulman, Gerald I., Samuel, Varman T. · 2013 · Diabetes
Cited by 152

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

We measured the mRNA and protein expression of the key gluconeogenic enzymes in human liver biopsy specimens and found that only hepatic pyruvate carboxylase protein levels related strongly with glycemia. We assessed the role of pyruvate carboxylase in regulating glucose and lipid metabolism in rats through a loss-of-function approach using a specific antisense oligonucleotide (ASO) to decrease expression predominantly in liver and adipose tissue. Pyruvate carboxylase ASO reduced plasma glucose concentrations and the rate of endogenous glucose production in vivo. Interestingly, pyruvate carboxylase ASO also reduced adiposity, plasma lipid concentrations, and hepatic steatosis in high fat–fed rats and improved hepatic insulin sensitivity. Pyruvate carboxylase ASO had similar effects in Zucker Diabetic Fatty rats. Pyruvate carboxylase ASO did not alter de novo fatty acid synthesis, lipolysis, or hepatocyte fatty acid oxidation. In contrast, the lipid phenotype was attributed to a decrease in hepatic and adipose glycerol synthesis, which is important for fatty acid esterification when dietary fat is in excess. Tissue-specific inhibition of pyruvate carboxylase is a potential therapeutic approach for nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-1311

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 152

Metadata

Authors
Kumashiro, N., Beddow, S. A., Vatner, D. F., Majumdar, S. K., Cantley, J. L., Guebre-Egziabher, F., Fat, I., Guigni, B., Jurczak, M. J., Birkenfeld, A. L., Kahn, M., Perler, B. K., Puchowicz, M. A., Manchem, V. P., Bhanot, S., Still, C. D., Gerhard, G. S., Petersen, K. F., Cline, G. W., Shulman, G. I., & Samuel, V. T.
Venue
Diabetes
Published
2013-06-14
Volume
62
Issue
7
Pages
2183-2194
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2150664194
Cited by
152
References
13
FWCI
4.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance. https://app.cochat.ai/papers/10.2337/db12-1311
The paper
Kumashiro, N., Beddow, S. A., Vatner, D. F., Majumdar, S. K., Cantley, J. L., Guebre-Egziabher, F., Fat, I., Guigni, B., Jurczak, M. J., Birkenfeld, A. L., Kahn, M., Perler, B. K., Puchowicz, M. A., Manchem, V. P., Bhanot, S., Still, C. D., Gerhard, G. S., Petersen, K. F., Cline, G. W., . . . Samuel, V. T. (2013). Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance. Diabetes. https://doi.org/10.2337/db12-1311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.